DYN Q3 2023 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$62M

Net Income

-$60M

EPS (Diluted)

$-0.99

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$205M

Total Liabilities

$53M

Stockholders' Equity

$152M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$62M	-$42M	-47.3%
Net Income	-$60M	-$41M	-45.5%